Your session is about to expire
← Back to Search
Radiation Therapy
Group 2: Peripherally Located Chest Wall Adjacent Tumors for Non-Small Cell Lung Cancer
N/A
Waitlist Available
Led By Matthew Harkenrider, MD
Research Sponsored by Loyola University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 104 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial will test the hypothesis that SBRT results in a higher rate of tumor control and longer overall survival compared to EBRT in medically inoperable early-stage NSCLC patients.
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 104 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~104 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Toxicity Evaluation
Secondary study objectives
Disease Specific Outcomes
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Group 3: Centrally Located TumorsExperimental Treatment1 Intervention
Centrally Located Tumors - SBRT
Group II: Group 2: Peripherally Located Chest Wall Adjacent TumorsExperimental Treatment1 Intervention
Peripherally Located Chest Wall Adjacent Tumors - SBRT
Group III: Group 1: Peripherally Located TumorsExperimental Treatment1 Intervention
Peripherally Located Tumors - SBRT
Find a Location
Who is running the clinical trial?
Loyola UniversityLead Sponsor
160 Previous Clinical Trials
31,378 Total Patients Enrolled
Matthew Harkenrider, MDPrincipal InvestigatorEdward Hines Jr. VA Hospital
1 Previous Clinical Trials
24 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger